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cense.Abstract Background: Tumor budding (TB) is showing increasing promise as a colorectal cancer
(CRC) prognosticator that is independent of TNM staging. b-Catenin is a component of the Wing-
less/Wnt signaling pathway that is bound to membrane-associated E-cadherin and is essential for its
correct position and function.
Methods: This study was designed to detect TB in 44 resected primary CRC cases and also to com-
pare b-catenin expression in the tumor budding sites (TBS) and in the tumor center. Tumor budding
was assessed in both H&E and pankeratin immunostained sections. Agreement between TB scoring
using pancytokeratin and H&E was tested. Also, typing of the tumor margin and determination of
degree of cytoplasmic pseudo-fragmentation was done. Tumor budding, cytoplasmic pseudofrag-
ments and b-catenin expression were related to known CRC prognosticators.
Results: Ten tumors (22.7%) showed low grade (LG) budding and 34 tumors (77.3%) showed high
grade (HG) budding. The 34 HG budding tumors were further subdivided into moderate and severe
(n= 13, n= 21, respectively) budding cancers. Twenty nine tumors (65.9%) showed LG cytoplas-
mic pseudofragments and 15 tumors (34.1%) showed HG pseudofragments. Scoring of TB on H&E
and pankeratin stained sections revealed moderate agreement (Kappa = .558; p=<.000).
A signiﬁcant relation between TB and cytoplasmic pseudofragments was observed (p= .009). Both
TB and cytoplasmic pseudofragments did not signiﬁcantly associate with clinicopathologic
parameters. Immunoreactivity of nuclear and cytoplasmic b-catenin was signiﬁcantly higher atawzy Moaaz Street, Smouha,
(S. El-Gendi).
Institute, Cairo University.
.
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2 S. El-Gendi, A. Al-GendiTBS compared to tumor center (p= .005, p= .000, respectively). In opposition, membranous b-
catenin expression was signiﬁcantly higher in the tumor center than in TBS (p= .001). Although,
nuclear b-catenin accumulation at TBS was noted, yet, it did not relate signiﬁcantly with both TB
and cytoplasmic pseudofragments around TBS (p= .649; p= .675, respectively). Also, nuclear
b-catenin immunoreactivity did not relate signiﬁcantly with the various clinicopathological
variables.
Conclusion: Pankeratin immunostaining facilitates typing of CRC invasive margin, and determina-
tion of the degree of TB and cytoplasmic pseudo-fragmentation. b-Catenin expression differs signif-
icantly between tumor center and TBS in CRC. Cut-offs for TB assessment should be uniﬁed and
further studies are recommended to allow a better understanding of this process before establishing
TB as a prognostic factor beyond the TNM staging in CRC.
ª 2011 National Cancer Institute, Cairo University. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license.Introduction
In most countries the decision whether or not to use adjuvant
treatment for colorectal carcinoma (CRC) depends mainly on
the clinicopathological staging that is carried out according to
the tumor node metastasis (TNM) staging system. There is
consensus that CRC patients with involved nodes will beneﬁt
from chemotherapy [1,2]; and rectal carcinomas inﬁltrating be-
yond the bowel wall are eligible for chemoradiation to reduce
the risk of local failure, regardless of nodal status [3]. However,
this stratiﬁcation excludes the small but signiﬁcant proportion
of patients (10–15% of the total) who, despite being staged as
low risk, follow an adverse clinical course with metachronous
metastatic disease. Therefore, prognostic factors in addition to
TNM are important issues for both clinical oncologists [1] and
surgical pathologists [4,5].
Tumor–host interaction at the invasive front of colorectal
cancer represents a critical interface where tumor progression
and tumor cell dissemination ensue [6,7], with loss of cytological
features of differentiation (de-differentiation of colorectal
carcinoma cells); this corresponds to tumor budding [8]. TB is
a peculiar pathologic feature of adenocarcinomas, especially
colorectal and pancreaticobiliary carcinomas [1]. Tumor bud-
dingdenotes the presence at the invasive front of a subset of colo-
rectal adenocarcinomas of tiny cords and small aggregates of
neoplastic epithelium that extend from neoplastic glands for a
short distance into a desmoplastic stroma [9]. A detailed mor-
phological study of TBhas been published byGabbert et al. [10].
The role of tumor budding in the surgical pathology of
colorectal carcinoma and its important link to tumor biology
has largely escaped the attention of histopathologists [9].
Disintegration of cell adhesion molecules with modulation of
E-cadherin-mediated adhesion is closely related to and is
involved in tumor budding [8].
b-Catenin is a component of the Wingless/Wnt signaling
pathway that is bound to membrane-associated E-cadherin
and is essential for its correct position and function [11].
Inactivation of the adenomatous polyposis coli (APC) gene
that is the earliest frequent event in CRC leads to a cytoplas-
mic and subsequent nuclear accumulation of b-catenin [12].
Nuclear b-catenin acts as a transcriptional activator that acti-
vates genes necessary for cell proliferation, differentiation and
invasive growth [8]. Thus, the intracellular distribution of b-
catenin has a strong impact on the phenotype (tumor morphol-
ogy) and behavior (i.e. aggressiveness) of tumor cells [8,13].This study was designed to detect TB in resected primary
colorectal carcinoma cases without pre-operative neoadjuvant
treatment and to compare the expression of b-catenin between
tumor budding sites and the tumor center. The histomorpholog-
ic features of tumor budding were assessed in H&E stained sec-
tions. Semiquantitative assessment of tumor budding at the
tumor invasive front was achieved in both H&E and pancyto-
keratin immunostained tissue sections. Typing of the tumor
margin, determination of the degree of TB and the degree of
cytoplasmic pseudo-fragmentation were performed more
accurately on the pancytokeratin immunostained slides. Tumor
budding, cytoplasmic pseudofragments and nuclear b-catenin
expressionwere related toknowncolorectal carcinomaprognos-
ticators including venous angioinvasion, lymphatic permeation,
serosal involvement, type of themargin, as well as the number of
regional lymph nodes involved by metastatic deposits.
Material and methods
Patients
The present study included 44 consecutive surgically excised
CRC specimens received at the Pathology Department,
Faculty of Medicine, University of Alexandria, from January
2007 to March 2009. We excluded patients who underwent
preoperative chemotherapy and emergency surgery. Patients’
ages ranged from 26 to 80 years. The study was approved by
Alexandria University, Faculty of Medicine Research Ethics
Committee.
The formalin ﬁxed parafﬁn-embedded (FFPE) tissue blocks
were retrieved from the computer ﬁles and archives of the
Pathology Department, Faculty of Medicine, Alexandria Uni-
versity. The original hematoxylin and eosin (H&E) stained sec-
tions of primary tumors were reviewed, and one parafﬁn block
showing the tumor invasive front was chosen from each case
for immunohistochemical studies.
Histological analysis of primary CRC features was done
and included: determination of tumor histological type, grade,
tumor growth pattern, lymphocytic inﬁltration at the advanc-
ing tumor margin, in addition to identifying tumor budding
foci by conventional H&E staining. Also assessment of the re-
gional lymph node status was done.
Staging was performed according to the tumor node metas-
tasis (TNM) staging system [14]. Tumor type was determined
by the criteria of the World Health Organization [15]. Growth
Figure 1 Low grade tumor budding at colorectal carcinoma
invasive front (pankeratin immunostain 100·).
Assessment of tumor budding in colorectal carcinoma: Correlation with b-catenin nuclear expression 3pattern and lymphocytic inﬁltration at the advancing tumor
margin were evaluated according to the criteria of Jass et al.
[16]. Clinical and pathological data including patient age,
sex, tumor site, size, and stage were obtained from the patho-
logical and clinical records.
Immunohistochemistry
Five micron-thick sections, of FFPE tissue blocks were cut and
mounted on coated slides. The sections were deparafﬁnized in
xylene and rehydrated in descending ethanol grades. Sections
were incubated for 10 min in 3% hydrogen peroxide to block
endogenous tissue peroxidase. For pankeratin immuno-
staining, enzymatic antigen retrieval was done using trypsin
(pre-heated to 37 C) by directly pipetting the solution onto
the tissue on the slide and incubating it for 15 min in a 37 C
incubator, whereas, for b-catenin heat retrieval was done in
microwave oven using EDTA 1 mM (pH 8.0) for 45 min.
Tissue sections were immunostained for pancytokeratin using
a ready to use monoclonal antibody clone [AE1/AE3]
(ab961), (Abcam, USA). Tissue sections were also stained for
b-catenin using a mouse monoclonal antibody clone 14/b-cate-
nin (Biocare Medical, LCC, USA) at a dilution of 1:100. The
antigen–antibody reaction was visualized by Thermo Scientiﬁc
UltraVision LP Detection System. Immunohistochemical reac-
tions were developed with diaminobenzidine and sections
counterstained with Harrris hematoxylin. All immunostains
were manually processed. Appropriate positive and negative
controls were included for each batch of slides.
Quantiﬁcation of tumor budding
Tumor budding was assessed semiquantitatively in both H&E
and pankeratin immunostained sections according to the
method proposed by Ueno et al. [17]. The tumor border was
scanned at 10· power in all cases and the area of most dense
budding was identiﬁed. In the center of this area, tumor buds
(single cells or clusters of up to 5 cells) were counted at 20·
magniﬁcation.
Cases were then divided into two groups according to the
number of tumor budding foci in the most dense ﬁeld using an
20· objective lens. Counts of 0–9 were classiﬁed as low-grade,
while counts of 10+ were classiﬁed as high-grade budding.
High-grade budding was further divided into counts of 10–19
(moderate) and 20+ (severe) [18]. Agreement between TB scor-
ing on H&E and pankeratin stained sections was tested.
Assessment of cytoplasmic fragments
Using pancytokeratin-immunostained sections, small non-
nucleated cytoplasmic fragments were detected around tumor
budding foci at the invasive tumor margin. Following the cri-
teria published by Shinto et al. [18] cytoplasmic fragments to
be counted had to be: at least 2 lm in diameter, non-nucleated,
lacking evidence of nuclear fragmentation, uniformly positive
for cytokeratin, smoothly contoured and free of surrounding
inﬂammatory cells. Scores for each case were the highest
number of fragments in a 20· objective lens ﬁeld, and accord-
ingly the 44 CRC cases were divided into low (0–9 fragments)
and high grade (10+ fragments) for cytoplasmic pseudo-
fragmentation [18].Evaluation of b-catenin immunostaining
Immunoreactivity of b-catenin was separately analyzed for the
tumor center and the tumor budding sites. Staining intensity of
membranous, cytoplasmic and nuclear b-catenin was graded as
absent (0), mild (1), moderate (2), or severe (3) [8]. Overexpres-
sion of nuclear b-catenin was deﬁned as a reactivity of >50%
of the tumor cell nuclei [19].
Statistics
Data were fed to the computer using the Predictive Analytics
Software (PASW Statistics 18). Qualitative data were de-
scribed using number and percent. Association between cate-
gorical variables was tested using the Chi-square test. When
more than 20% of the cells have expected count less than 5,
correction for Chi-square was conducted using the Fisher’s
Exact test (FET) or Yates’ Chi-square test. The distributions
of quantitative variables were tested for normality using the
Kolmogorov–Smirnov test which revealed that data was not
normally distributed. Thus, non-parametric statistics were
applied. Quantitative data were described using median, mini-
mum and maximum. Differences between two related quanti-
tative variables were assessed using the Wilcoxon Signed
Ranks (z) Test. An inter-rater reliability analysis using the
Kappa statistic was performed to determine consistency
between different diagnostic tools. Signiﬁcance test results
are quoted as two-tailed probabilities. Signiﬁcance of the
obtained results was judged at the 5% level.
Results
Clinicopathologic data
The studied cases included 12 male and 32 female with M:F
3:8. The age of patients ranged between 26 and 80 years
(mean = 53.2 ± 13.6 years, median = 55.0 years). Eleven
tumors (25%) were located in the right colon, 26 (59.1%) in
the left colon, and 7 (15.9%) were in the rectum.
Immunohistochemistry
Using pancytokeratin immunostaining, the counting of tumor
budding (TB) and cytoplasmic pseudofragments using
Figure 2 Colorectal carcinoma showing high grade tumor
budding that can be easily detected by pancytokeratin at low
power (pankeratin immunostain 40·).
Figure 3 Colorectal carcinoma invasive front revealing high
grade budding and high grade cytoplasmic pseudofragments.
Multiple cytoplasmic fragments are seen as round cytokeratin-
immunostained spots without a nucleus at the invasive front
around tumor budding foci (pankeratin immunostain 400·).
Table 1 Relation between tumor budding and cytoplasmic
pseudofragments in the 44 studied CRC cases.
Cytoplasmic pseudofragments Total Fisher’s Exact
test (p value)
Low grade High grade
Tumor budding
Low grade 10 0 10 6.694 (.009)
34.5% .0% 22.7%
High grade 19 15 34
65.5% 100.0% 77.3%
Total 29 15 44
100.0% 100.0% 100.0%
High grade budding
Moderate 9 4 13 1.521 (.217)
47.4% 26.7% 38.2%
Severe 10 11 21
52.6% 73.3% 61.8%
Total 19 15 34
100.0% 100.0% 100.0%
Signiﬁcant relations are in boldface.
4 S. El-Gendi, A. Al-Gendi20· objective lens was done. Low grade budding (0–9 budding
foci) was detected in 10 tumors (22.7%) (Fig. 1) whereas high
grade budding (10+ budding foci) was detected in 34 tumors
(77.3%) (Fig. 2). The 34 high grade budding tumors were
further stratiﬁed based on the number of tumor budding
sites (TBS) into moderate (10–19 budding foci) and severe
(20+ budding foci) (n= 13; 38.2%, n= 21; 61.8%, respec-
tively) budding cancers. Twenty nine tumors (65.9%) showed
low grade cytoplasmic pseudofragments (0–9 fragments) and
15 tumors (34.1%) showed high grade pseudofragments
(10+ fragments) (Fig. 3).
There was a strong signiﬁcant relationship between tumor
budding and cytoplasmic pseudofragments (FET; p = .009).
All 10 low-grade tumor budding cancers (0–9 budding foci)Table 2 Relation between tumor budding and clinicopatho-
logic parameters in colorectal carcinoma cases.
IHC budding
Low grade High grade
No. % No. %
Age (years)
25- 5 50.0 15 44.1 0.001F
55- 5 50.0 19 55.9 .975
Sex
Male 2 20.0 10 29.4 0.034F
Female 8 80.0 24 70.6 .853
Site of tumor
Right colon 1 10.0 10 29.4 1.079Y
Left colon 8 80.0 18 52.9 0.583
Rectal 1 10.0 6 17.6
Tumor gross appearance
Annular 2 20.0 8 23.5 0.071Y
Fungating 4 40.0 10 29.4 .965
Ulcer 4 40.0 16 47.1
Tumor grade
Well diﬀerentiated 1 10.0 10 29.4 0.912Y
Moderately diﬀerentiated 9 90.0 22 64.7 .633
Poorly diﬀerentiated 0 .0 2 5.9
Tumor size (T)
T2 1 10.0 3 8.8 0.681Y
T3 9 90.0 30 88.2 .711
T4 0 .0 1 2.9
Nodal status (N)
N0 3 30.0 19 55.9 2.103Y
N1 5 50.0 7 20.6 .349
N2 2 20.0 8 23.5
Nodal status (N)
ve 3 30.0 19 55.9 1.165F
+ve 7 70.0 15 44.1 .280
LVI
Not detected 8 80.0 30 88.2 0.02Y
Detected 2 20.0 4 11.8 .888
Angioinvasion
Not detected 10 100.0 33 97.1 0.433Y
Detected 0 .0 1 2.9 .510
Y Yates’ Chi-square.
F Fisher’s Exact test.
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34) of high grade tumor budding cancers showed low grade
pseudofragments and 44.1% (15/34) of high-grade tumor bud-
ding cancers (10+ budding foci) showed high grade pseudo-
fragments. Thus, within the high grade budding tumors
(n= 34), severe budding did not signiﬁcantly associate with
cytoplasmic pseudo-fragments (FET; p= .217) (Table 1).
Both TB and cytoplasmic pseudofragments did not show
statistically signiﬁcant associations with clinicopathologic
parameters such as gender, age, tumor site, size, grade, lym-
phovascular invasion, and lymph node metastasis (Tables 2
and 3).
In this study, we compared b-catenin immunoreactivity at
tumor center and tumor budding sites. A statistically signiﬁ-
cant difference was detected as regards b-catenin immunoreac-Table 3 Relation between cytoplasmic pseudo-fragmentation
and clinicopathologic parameters in colorectal carcinoma cases.
IHC pseudofragments Chi-square
(p value)
Low grade High grade
No. % No. %
Age (years)
25- 16 55.2 4 26.7 3.240F
55- 13 44.8 11 73.3 .072
Sex
Male 7 24.1 5 33.3 0.085F
Female 22 75.9 10 66.7 .771
Site of tumor
Right colon 4 13.8 7 46.7 5.413Y
Left colon 18 62.1 8 53.3 .247
Rectal 7 24.1 0 .0
Tumor gross appearance
Annular 7 24.1 3 20.0 0.131Y
Fungating 10 34.5 4 26.7 .937
Ulcer 12 41.4 8 53.3
Tumor grade
Well diﬀerentiated 7 24.1 4 26.7 0.1Y
Moderately diﬀerentiated 21 72.4 10 66.7 .951
Poorly diﬀerentiated 1 3.4 1 6.7
Tumor size (T)
T2 2 6.9 2 13.3 0.206Y
T3 27 93.1 12 80.0 .902
T4 0 .0 1 6.7
Nodal status (N)
N0 12 41.4 10 66.7 1.752Y
N1 10 34.5 2 13.3 .416
N2 7 24.1 3 20.0
Nodal status (N)
ve 12 41.4 10 66.7 1.618Y
+ve 17 58.6 5 33.3 .203
LVI
Not detected 25 86.2 13 86.7 0.177Y
Detected 4 13.8 2 13.3 .673
Angioinvasion
Not detected 29 100.0 14 93.3 .115Y
Detected 0 .0 1 6.7 .734
Y Yates’ Chi-square.
F Fisher’s Exact test.tivity between the tumor center and TBS. Immunoreactivity of
both nuclear and cytoplasmic b-catenin was signiﬁcantly
higher at TBS than in the tumor center (z= 2.840; p= .005Figure 4 Immunohistochemical scores of b-catenin in colorectal
adenocarcinomas. There is a signiﬁcant difference in the scores of
b-catenin between tumor border and tumor center. C = cytoplas-
mic immunoreactivity; N = nuclear immunoreactivity; M=
membranous immunoreactivity.
Figure 5 b-Catenin immunostaining in colorectal adenocarci-
noma. Note the strong cytoplasmic and membranous staining
pattern of neoplastic glands at the tumor center (100·).
Figure 6 Colorectal carcinoma featuring neoplastic glands at
tumor center revealing strong membranous and cytoplasmic b-
catenin immunoreactivity (400·).
Table 4 Relation between the degree of tumor budding and b-
catenin immunoreactivity at tumor center and tumor border in
CRC.
Tumor budding in CRC Fisher’s
Exact test
(p value)
Low grade High grade
No. % No. %
b-Catenin cytoplasmic staining at tumor center
ve 0 0.0 0 0.0
+ve 10 100.0 34 100.0
b-Catenin nuclear staining at tumor center
ve 8 80.0 34 100.0 1.084F
+ve 2 20.0 0 .0 .540
b-Catenin membranous staining at tumor center
ve 4 40.0 20 58.8 .570
6 S. El-Gendi, A. Al-Gendiand z= 5.406; p= .000, respectively), In opposition, membra-
nous b-catenin expression was signiﬁcantly higher in the tumor
center than in tumor budding foci (z= 3.416; p= .001)
(Figs. 4–6).
An overexpression of nuclear b-catenin was deﬁned as a
reactivity of >50% of the nuclei. Accumulation of nuclear
b-catenin at the invasive front (TB sites) was observed in 37
cases (84.1%) compared to only 2 cases (4.6%) that also
showed nuclear b-catenin overexpression in tumor cells at
the tumor center in addition to TBS (Figs. 7 and 8). When
these staining results were related to the various clinical and
pathological variables, no signiﬁcant associations could be
observed.
Nuclear b-catenin at the invasive front failed to relate sig-
niﬁcantly with both the degree of budding (FET; p= 0.675)
and cytoplasmic pseudofragments (FET; p= 0.649) at the tu-
mor invasive front (Tables 4 and 5).
The need for pancytokeratin immunostaining and tumor
budding counting may be met by reservations on the part of
histopathologists with a busy workload. With this practical as-
pect in mind, simple scoring of TB on H&E sections was doneFigure 7 Microscopic appearance of the invasive front in
colorectal carcinoma immunostained for b-catenin. Note that
budding tumor cells express nuclear and cytoplasmic b-catenin
(100·).
Figure 8 Budding tumor cells at invasive front in colorectal
carcinoma demonstrating strong nuclear b-catenin accumulation
in addition to the cytoplasmic immunostaining (400·).to test if it could work as a surrogate. Thus, all 44 studied cases
were reviewed and classiﬁed as high or low in tumor budding
by simple subjective scoring of H&E sections. Using this+ve 6 60.0 14 41.2 .450
b-Catenin cytoplasmic staining at tumor border
ve 0 0.0 0 0.0
+ve 10 100.0 34 100.0
b-Catenin nuclear staining at tumor border
ve 2 20.0 5 14.7 .285F
+ve 8 80.0 29 85.3 .675
b-Catenin membranous staining at tumor border
ve 10 100.0 28 82.4 .783F
+ve 0 .0 6 17.6 .394
Table 5 Relation between the degree of cytoplasmic pseudo-
fragments and b-catenin immunoreactivity at tumor center and
tumor border in CRC.
Cytoplasmic pseudofragments in CRC Fisher’s
Exact test
(p value)
Low grade High grade
No. % No. %
b-Catenin cytoplasmic staining at tumor center
ve
+ve 29 100.0 15 100.0
b-Catenin nuclear staining at tumor center
ve 27 93.1 15 100.0 1.084
+ve 2 6.9 0 .0 (.540)
b-Catenin membranous staining at tumor center
ve 17 58.6 7 46.7 1.104
+ve 12 41.4 8 53.3 (.472)
b-Catenin cytoplasmic staining at tumor border
ve
+ve 29 100.0 15 100.0
b-Catenin nuclear staining at tumor border
ve 4 13.8 3 20.0 .162
+ve 25 86.2 12 80.0 (.649)
b-Catenin membranous staining at tumor border
ve 26 89.7 12 80.0 2.043
+ve 3 10.3 3 20.0 (.310)
Figure 9 Colorectal carcinoma invasive margin featuring neo-
plastic glands with budding tumor cells lurking into a desmoplas-
tic stroma (H&E 40·).
Figure 10 High power view showing numerous foci of tumor
budding at the invasive front of colorectal carcinoma. Budding
foci are seen as either isolated single cell or small clusters of up to
ﬁve carcinoma cells (H&E 400·).
Table 6 Agreement between tumor budding assessed on
conventional H&E sections and tumor budding assessed on
pankeratin immunostained sections in CRC.
Tumor budding by H&E Total Kappa
High grade Low grade
TB by pankeratin immunostain
Low grade No. 10 0 10 .558 (<.000)
% 22.7 .0 22.7
High grade No. 9 25 34
% 20.5 56.8 77.3
Total Count 19 25 44
% 43.2 56.8 100.0
Signiﬁcant relations are in boldface.
Assessment of tumor budding in colorectal carcinoma: Correlation with b-catenin nuclear expression 7approach, of 34 tumors classiﬁed as bud high on pancytoker-
atin immunostain, only 25 cases (73.5%) were classiﬁed as high
in tumor budding on H&E sections. Conversely, all 10 cases
rated bud low on pancytokeratin immunostain, were also
classiﬁed as low in tumor budding on H&E sections. The
agreement between the two methods (H&E and pankeratin
immunostain) was moderate; Kappa = .558 (p< .000)
(Figs. 9, 10 and Table 6).Thus, there is a tendency to underestimate tumor budding
on H&E sections and in a signiﬁcant number of cases using
pancytokeratin immunostains, surprisingly higher numbers
of tumor buds will be seen lurking in a desmoplastic stroma
closely intertwined with plump ﬁbroblasts.
Discussion
Diagnosis and treatment of CRC have evolved considerably
during recent years. Speciﬁcally, decisions for or against
limited or full resections, and for or against adjuvant therapy
are made largely on the basis of the histopathological ﬁndings
[9].
This study was undertaken to investigate the occurrence
and histomorphologic features of TB in primary untreated
CRC. TB and the related phenomenon of cytoplasmic pseu-
do-fragmentation were assessed semiquantitatively relating
them to known CRC prognosticators. Also, expression of b-
catenin between TBS and tumor center was compared to eval-
uate whether EMT occurs at TBS.
Although TB is showing increasing promise in clinicopath-
ological studies as a prognostic factor in CRC independent of
TNM staging [1,9,20–22], still yet, it has not been implemented
into daily diagnostic routine because of absence of standard-
ized scoring systems and sufﬁcient evidence of inter-observer
reproducibility for selected evaluation methods [23].
Prerequisites for any parameter to be valid as a prognostic
marker include simplicity, reproducibility and objectivity. Tu-
mor budding can be assessed objectively by counting on H&E
stained sections representing tumor invasive front, however,
cytokeratin immunostaining allows more accurate assessment.
Previous studies revealed that the reproducibility among hist-
opathologists of budding measured either by intraobserver
semiquantitative agreement or by interobserver agreement
with regard to the presence or absence was high [8,20,24].
Two different types of scoring systems have been proposed:
subjective and more quantitative/objective. In 1993, Hase et al.
[25] presented a system based on using a 2-tier method (none
or minimal versus moderate or severe). Nakamura et al.
[22,26] described TB along the entire invasive margin using a
4-tier method (none, mild <1/3, moderate 1/3–2/3 and severe
>2/3). The group of Ueno et al. reported quantitative scoring
by counting the number of buds within the ﬁeld of most dense
TB using a 20· objective lens with a cut-off of 10 buds with
8 S. El-Gendi, A. Al-Gendiinter-observer agreement of Kappa = 0.84 [17,20]. Wang et al.
evaluated ﬁve randomly selected areas, each was given a score
based on presence (at least one bud) or absence of TB in each
ﬁeld (area 0.949 mm2) and they document an interobserver
agreement of Kappa = 0.75 [27]. Prall et al. [1] scored panker-
atin-stained tumor buds using an established statistical cut-
point determination method (receiver operating characteristic
(ROC) curve analysis) classifying tumors of P25 buds/ﬁeld
in a 0.785 mm2 ﬁeld of vision (250·) as positive, with strong
inter-observer agreement of Kappa = 0.874.
In the present study, semiquantitative assessment of TB was
undertaken on pan-keratin stained sections. At low magniﬁca-
tion, tumor buds were highlighted extremely well and the selec-
tion of a counting area as well as the counting itself was an
easy and rapid procedure, an aspect which is important if an
application in routine surgical pathology is envisioned. We
also semiquantitatively assessed TB on H&E stained sections
to assess the consistency between both methods (H&E versus
pankeratin immunostain). Although the agreement between
the two methods was moderate; Kappa = .558 (p< .000),
however, a tendency to underestimate TB on H&E sections
was observed as nine cases (26.5%) classiﬁed as bud low on
H&E sections, using pancytokeratin immunostains, surpris-
ingly showed higher numbers of tumor buds lurking in a des-
moplastic stroma closely intertwined with plump ﬁbroblasts.
Thus, these nine cases were classiﬁed as bud high based on
pankeratin immunostained sections.
The morphological link between TB and tumor cell migra-
tion at the invasive margin by pseudopod formation was re-
cently proposed by Shinto et al. [18] who pointed out that,
on high magniﬁcation in the immediate vicinity of tumor buds,
pancytokeratin immunostain revealed non-nucleated cytoplas-
mic droplets to which the term ‘cytoplasmic pseudo-fragments’
was applied after demonstrating on step sections that these
structures are continuous with the cytoplasm of budding
tumor cells. These cytoplasmic pseudo-fragments were inter-
preted as podia-like cytoplasmic extensions which are thought
to be a marker of an activated budding phenotype associated
with cell motility and increased invasiveness during tumor cell
migration.
Similarly, and to the best of our knowledge, we are the sec-
ond study to document the presence of this new feature. Cyto-
plasmic pseudo-fragments were detected in the stroma
surrounding budding foci and were found to strongly associate
with TB (p= .009). Also, in accordance with Shinto et al. [18]
our study revealed the absence of a signiﬁcant relation between
the extent of budding (within CRCs showing high-grade bud-
ding) and cytoplasmic pseudo-fragments (p= .217), thus,
implying that the extent of budding and cytoplasmic pseudo-
fragments are indicative of different mechanisms of tumor
aggressiveness.
Epithelial mesenchymal transition (EMT) is proposed as a
critical mechanism for the acquisition of malignant phenotypes
by epithelial cells. In CRC, tumor cells having undergone
EMT are histologically represented by the presence of tumor
buds [23]. The suggested scenario is: adhesion junctions medi-
ated by E-cadherin are broken up and tumor cell complexes
dissociate, reorganization of the actin cytoskeleton allows bud-
ding tumor cells to extend podia into the migration direction.
Tumor budding in this scenario is highly dynamic [9].
This study, as putative direct evidence ofWnt dysregulation,
revealed a striking pattern of b-catenin immunostaining inCRC. Cytoplasmic and nuclear b-catenin expression increased
signiﬁcantly in TBS compared to tumor center sites, whereas,
membranous b-catenin decreased signiﬁcantly in TBS com-
paredwith the tumor center.When all these staining results were
related to the various clinical and pathological variables, no sig-
niﬁcant associations were observed. The ﬁnding that tumor
buds shows a strong and uniform nuclear b-catenin staining
with concomitant loss of membranous E-cadherin expression
was reported by Zlobec and Lugli [23] and further augment
previous ﬁndings of EMT studies [9,28–31] which reported that
toward the center of a CRC the neoplastic glands show
membranous b-catenin immunostaining, but in tumor buds this
membranous immunostaining is lost, and instead, immuno-
staining of the tumor cell nuclei is very strong.
In our study, nuclear b-catenin accumulation at the tumor
invasive front (TBS) failed to relate signiﬁcantly with the de-
gree of budding (p= 0.649), a ﬁnding that was reported and
explained by Shinto et al. [18] stating that forms of budding
that result from loss of cell cohesion, without additional
activation of invasiveness, may be less dependent on Wnt path-
way dysregulation. However, in opposition to Shinto et al.
[18], in our study, nuclear b-catenin accumulation at TBS
did not signiﬁcantly relate with cytoplasmic pseudofragments
(p= 0.675), which may be explained by limited sample size.
Thus, TB involves two independent processes. These are
loss of cellular cohesion – as reﬂected by the degree of TB –
and cellular activation leading to increased invasiveness. This
latter process is associated with the ﬁnding of cytoplasmic
pseudo-fragments and is more dependent on dysregulation of
the Wnt signaling pathway [18].
In summary, we document that pankeratin immunostain
facilitates accurate assessment of TB compared to conven-
tional H&E, and also highlights the phenomenon of cytoplas-
mic pseudo-fragmentation. Nuclear b-catenin accumulation at
TBS denotes occurrence of EMT with underlying aberrations
of E-cadherin mediated adhesion. This is followed by cell acti-
vation and increased invasiveness that is dependant on Wnt
pathway dysregulation as reﬂected by cytoplasmic pseudo-
fragmentation. Thus, the extent of budding and cytoplasmic
pseudo-fragments is indicative of different mechanisms of
tumor aggressiveness. Cut-offs should be uniformly deﬁned
before TB enters routine surgical pathology practice, and
before establishing TB as a CRC prognosticator beyond
TNM. Other studies in the ﬁeld of TB are highly needed to
uncover its underlying cellular biologic basis.References
[1] Prall F, Nizze H, Barten M. Tumor budding as prognostic factor
in stage I/II colorectal carcinoma. Histopathology
2005;47:17–24.
[2] Haydon A. Adjuvant chemotherapy in colon cancer: what is the
evidence? Int Med J 2003;33:119–24.
[3] Van Cutsem E, Dicato M, Wils J, Cunningham D, Diaz-Rubio
E, Glimelius B, et al. Adjuvant treatment of colorectal cancer
(current export opinion derived from the third international
conference: perspectives in colorectal cancer, Dublin 2001). Eur
J Cancer 2002;38(11):1429–36.
[4] Chapuis PH, Dent OF, Bokey EL, Newland RC, Sinclair G.
Adverse histopathological ﬁndings as a guide to patient
management after curative resection of node-positive colonic
cancer. Br J Surg 2004;91:349–54.
Assessment of tumor budding in colorectal carcinoma: Correlation with b-catenin nuclear expression 9[5] Petersen VC, Baxter KJ, Love SB, Shepherd NA. Identiﬁcation
of objective pathological prognostic determinants and models of
prognosis in Dukes B colon cancer. Gut 2001;51:65–9.
[6] Zlobec I, Lugli A. Invasive front of colorectal cancer: dynamic
interface of pro-/anti-tumor factors. World J Gastroenterol
2009;15(47):5898–906.
[7] Natalwala A, Spychal R, Tselepis C. Epithelial–mesenchymal
transition mediated tumourigenesis in the gastrointestinal tract.
World J Gastroenterol 2008;14:3792–7.
[8] Tae Jung Jang. Expression of E-cadherin and b-catenin is
altered at tumor budding sites, whose number is associated with
the progression of colorectal carcinoma. Korean J Pathol
2009;43:523–7.
[9] Prall F. Tumour budding in colorectal carcinoma.
Histopathology 2007;50:151–62.
[10] Gabbert H, Wagner R, Moll R, Gerharz CD. Tumour
dedifferentiation: an important step in tumour invasion. Clin
Exp Metastasis 1985;3:257–79.
[11] Barth AI, Na_thke IS, Nelson WJ. Cadherins, catenins and APC
protein: interplay between cytoskeletal complexes and signaling
pathways. Curr Opin Cell Biol 1997;9:683–90.
[12] Korinek V, Barker N, Morin PJ, van Wichen D, de Weger R,
Kinzler KW, et al. Constitutive transcriptional activation by a
beta-catenin–Tcf complex in APC/ colon carcinoma. Science
1997;275:1784–7.
[13] Brabletz T, Jung A, Reu S, Porzner M, Hlubek F, Kunz-
Schughart LA, et al. Variable b-catenin expression in colorectal
cancers indicates tumor progression driven by the tumor
environment. Proc Natl Acad Sci USA 2001;98:10356–61.
[14] Sobin LH, Wittekind CH, editors. UICC TNM classiﬁcation of
malignant tumours. New York: Wiley-Liss; 1997.
[15] Jass JR, Sobin LH, editors. World Health Organization
international histological classiﬁcation of tumours.
Histological typing of intestinal tumours. Berlin: Springer-
Verlag; 1989.
[16] Jass JR, Ajioka Y, Alen JP, Chan YF, Cohen RJ, Nixon JM,
et al. Assessment of invasive growth pattern and lymphocytic
inﬁltration in colorectal cancer. Histopathology 1996;28:543–8.
[17] UenoH,MochizukiH,HashiguchiY, ShimazakiH,Aida S,Hase
K, et al. Risk factors for an adverse outcome in early invasive
colorectal carcinoma. Gastroenterology 2004;127:385–94.
[18] Shinto E, Mochizuki H, Ueno H, Matsubara O, Jass JR. A
novel classiﬁcation of tumour budding in colorectal cancer
based on the presence of cytoplasmic pseudo-fragments around
budding foci. Histopathology 2005;47:25–31.
[19] Baldus SE, Mo¨nig SP, HuxeS S, Landsberg S, Hanisch FG,
Engelmann K, et al. MUC1 and nuclear b-catenin arecoexpressed at the invasion front of colorectal carcinomas and
are both correlated with tumor prognosis. Clin Cancer Res
2004;10:2790–6.
[20] Ueno H, Muirphy J, Jass JR, Mochizuki H, Talbot IC. Tumour
‘budding’ as an index to estimate the potential of aggressiveness
in rectal cancer. Histopathology 2002;40:127–32.
[21] Okuyama T, Nakamura T, Yamaguchi M. Budding is useful to
select high-risk patients in stage II well-differentiated or
moderately differentiated colon adenocarcinoma. Dis Colon
Rectum 2003;46:1400–6.
[22] Nakamura T, Mitomi H, Kikuchi S, Ohtani Y, Sato K.
Evaluation of the usefulness of tumor budding on the
prediction of metastasis to the lung and liver after curative
excision of colorectal cancer. Hepatogastroenterology
2005;52:1432–5.
[23] Zlobec I, Lugli A. Epithelial mesenchymal transition and tumor
budding in aggressive colorectal cancer: tumor budding as
oncotarget. Oncotarget 2010;1:651–61.
[24] Okuyama T, Oya M, Yamaguchi M. Budding (sprouting) as a
useful prognostic marker in colorectal mucinous carcinoma. Jpn
J Clin Oncol 2002;32:412–6.
[25] Hase K, Shatney C, Johnson D, Trollope M, Vierra M.
Prognostic value of tumour ‘budding’ in patients with
colorectal cancer. Dis Colon Rectum 1993;36:627–35.
[26] Nakamura T, Mitomi H, Kanazawa H, Ohkura Y, Watanabe
M. Tumor budding as an index to identify high-risk
patients with stage II colon cancer. Dis Colon Rectum
2008;51:568–72.
[27] Wang LM, Kevans D, Mulcahy H, O’Sullivan J, Fennelly D,
Hyland J, et al. Tumor budding is a strong and reproducible
prognostic marker in T3N0 colorectal cancer. Am J Surg Pathol
2009;33:134–41.
[28] Brabletz T, Jung A, Hermann K, Gu¨nther K, Hohenberger W,
Kirchner T. Nuclear overexpression of the oncoprotein b-
catenin in colorectal cancer is localized predominantly at the
invasion front. Pathol Res Pract 1998;194:701–4.
[29] Horkko TT, Klintrup K, Makinen JM, Napankangas JB,
Tuominen HJ, Makela J, et al. Budding invasive margin and
prognosis in colorectal cancer: no direct association with beta-
catenin expression. Eur J Cancer 2006;42:964–71.
[30] Brabletz T, Hlubek F, Spaderna S, Schmalhofer O, Hiendlmeyer
E, Jung A, et al. Invasion and metastasis in colorectal cancer:
epithelial–mesenchymal transition, mesenchymal–epithelial
transition, stem cells and beta-catenin. Cells Tissues Organs
2005;179:56–65.
[31] Brabletz T. Tumor budding in colorectal cancer. New
York: Nova Science Publishers, Inc.; 2006 [chapter 4].
